Citryll and Lonza Enter Into Partnership to Manufacture NETosis Inhibiting Antibody CIT-013
The Netherlands-based biotech Citryll and CDMO Lonza announced a partnership to develop and manufacture Citryll’s tACPA therapeutic antibody CIT-013. CIT-013 targets Neutrophil…
Read More...
Read More...
